Scientist, Cellular Reprogramming and Engineering  
Job Code 334LF

Description
Fate’s Cellular Reprogramming and Engineering Group is seeking a skilled and highly motivated cell biologist to support ongoing cellular reprogramming and engineering research to further the development of novel off-the-shelf cellular therapeutics for the treatment of cancer and other disorders. The successful candidate will be responsible for playing a key role in the research and development of the company’s induced pluripotent stem cell (iPSC) platform. Ideally, the candidate will have strong expertise in cell culture, culture of pluripotent cells, and genetic engineering of human cells using various editing tools. The position includes collaboration with internal R&D, process development, quality assurance, and regulatory groups and external partners including our renowned academic research collaborators. The position also has the opportunity to lead various programs from inception to regulatory filings, providing a unique experience to play a major role in product development of off-the-shelf cell therapies. This is a full-time position and located at our corporate headquarters in San Diego, CA.

Responsibilities
• Design, execute, and analyze experiments to advance company’s iPSC platform  
• Reprogramming of somatic cells into iPSCs and characterization of generated iPSC lines  
• Genetic editing/engineering of various cell populations, including lentiviral transduction and CRISPR engineering, and phenotypic and functional characterization related to the genetic modulation  
• Participate and potentially lead the multiple stages of product development including R&D, IND-enabling activities, and cell bank derivation  
• Strong experimental design and troubleshooting skills, can document laboratory procedures and experiments with great attention to detail  
• Draft and execute SOPs/batch records and follow process documentation  
• Collaborate and coordinate with cross-functional research and development teams to advance program objectives  
• Presentation of data to project group and wider research organization

Qualifications
• Ph.D. in a biological science discipline with 3 years of post-doctoral experience in a biotechnology, pharmaceutical, or academic setting  
• Strong expertise and experience in cellular reprogramming, pluripotent stem cell culture and characterization, and genome modification of human iPSCs  
• Experience in multi-parameter flow cytometry is desirable  
• Demonstrated ability to work both independently and in a team-oriented environment  
• Excellent communication, attention to detail, and time management/organizational skills  
• Positive outlook and a team-oriented attitude  
• Demonstrated scientific track record through relevant publications and/or patents

Working Conditions and Physical Requirements
• Will require working with cells and cell lines of human origin  
• Occasional weekend and/or evening hours as necessary  
• 100% on-site work at corporate headquarters in San Diego, CA
The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 334LF.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.